正大天晴与赛诺菲达成超15亿独家授权;诺和诺德MASH新适应症拟纳入优先审评;全球首款宫颈癌前病变无创治疗药物获批上市

药财社
Mar 05

●药闻快报▲关注药财社聚焦医药界▲1正大天晴与赛诺菲达成超15亿独家授权3月4日,中国生物制药宣布,其附属公司正大天晴与赛诺菲达成独家授权协议,授予后者在全球范围内开发、生产及商业化口服小分子JAK/ROCK抑制剂罗伐昔替尼的独家许可。根据条款,中国生物制药将获得1.35亿美元首付款,以及最高13.95亿美元的开发、监管及销售里程碑付款,总金额超15亿美元,并享有基于年度净销售额的最高双位数阶梯式...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10